---
title: "Imlifidase in Kidney transplantation in highly sensitized patients: References"
description: "Reference list for the formulary evidence report on Imlifidase in Kidney transplantation in highly sensitized patients. 84 cited documents."
canonical: "https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Imlifidase in Kidney transplantation in highly sensitized patients: References

<a id="references"></a>

## 5 References

1. [Al-Salama (2020)](https://pubmed.ncbi.nlm.nih.gov/33058042/)
2. [Axelrod et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12404663/)
3. [Beaudrey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826255/)
4. [Bockermann et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9213077/)
5. [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf)
6. [Chandramohan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39202740/)
7. [ClinicalTrials.gov NCT05753930](https://clinicaltrials.gov/study/NCT05753930)
8. [Couzi et al. (2023)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2023.11244/full)
9. [Darwish et al. (2020)](https://link.springer.com/article/10.1186/s42506-020-00058-7)
10. [Davanzo et al. (2025)](https://d-nb.info/1366870824/34)
11. [de Weerd et al. (2023)](https://journals.lww.com/transplantjournal/fulltext/2023/01000/re__imlifidase_generated_single_cleaved_igg_.35.aspx)
12. [Devriese et al. (2025)](https://onlinelibrary.wiley.com/doi/full/10.1111/tan.70502)
13. [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)
14. [EU Clinical Trials Register 2016-002064-13](https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002064-13/results)
15. [European Medicines Agency Idefirix EPAR](https://www.ema.europa.eu/en/medicines/human/EPAR/idefirix)
16. [European Medicines Agency Idefirix product information (2026)](https://www.ema.europa.eu/en/documents/product-information/idefirix-epar-product-information_en.pdf)
17. [Furian et al. (2024)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12475/full)
18. [Furian et al. (2025)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13886/full)
19. [Ge et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32732834/)
20. [Guney et al. (2026)](https://www.sciencedirect.com/science/article/abs/pii/S0955470X26000169)
21. [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)
22. [Hamdini et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42592609/)
23. [Hannachi et al. (2026)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1728855/full)
24. [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/)
25. [Hansa Biopharma BLA submission announcement (2025)](https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-submits-bla-to-fda-for-imlifidase-in-desensitization-for-kidney-transplantation/)
26. [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)
27. [Hansa Biopharma ConfIdeS ATC 2026 plenary abstract announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-announces-confides-phase-3-abstract-selected-for-whats-hot-whats-new-plenary-at-atc-2026/)
28. [Hansa Biopharma ConfIdeS primary endpoint announcement (2025)](https://www.hansabiopharma.com/media/press-releases/2025/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation/)
29. [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/)
30. [Hansa Biopharma imlifidase page](https://www.hansabiopharma.com/our-science/imlifidase/)
31. [Hansa Biopharma PDUFA action date announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026/)
32. [Hansa Biopharma regulatory status page](https://www.hansabiopharma.com/our-science/regulatory-status/)
33. [Hansa Medical (2018)](https://www.hansabiopharma.com/media/press-releases/2018/the-american-journal-of-transplantation-publishes-results-from-hansa-medicals-first-phase-ii-study-with-ides/)
34. [Haute Autorité de Santé (2022)](https://www.has-sante.fr/jcms/p_3332338/en/idefirix-imlifidase)
35. [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/desensitisation-with-imlifidase-prior-to-kidney-transplant-in-highly-sensitised-children-dinky/)
36. [Hernández-Velasco et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41050132/)
37. [Houp and Seifert (2025)](https://www.amjtransplant.org/article/S1600-6135%2825%2902388-3/fulltext)
38. [HRSA Organ Procurement and Transplantation Network](https://www.hrsa.gov/optn/policies-bylaws/public-comment/remove-cpra-99-100-form-highly-sensitized-kidney-candidates)
39. [Huang et al. (2022)](https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.16828)
40. [Idefirix UK Summary of Product Characteristics](https://www.medicines.org.uk/emc/product/13155/smpc)
41. [Jackson (2026)](https://pubmed.ncbi.nlm.nih.gov/41631379/)
42. [Jackson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32065704/)
43. [Jaffe et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11723687/)
44. [Jaffe et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40320584/)
45. [Jordan (2025b)](https://pubmed.ncbi.nlm.nih.gov/40451389/)
46. [Jordan et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28767349/)
47. [Jordan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8294837/)
48. [Jordan et al. (2025a)](https://www.amjtransplant.org/article/S1600-6135%2824%2900742-1/fulltext)
49. [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)
50. [Kanbay et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10949912/)
51. [Kapturczak et al. (2026)](https://app.tts2026.org/program_view/lecture?id=765)
52. [Kjellman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9290474/)
53. [Krishnan et al. (2024)](https://indianjnephrol.org/imlifidase-is-it-the-magic-wand-in-renal-transplantation/)
54. [Kuypers et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40320582/)
55. [Lauzon et al. (2025)](https://www.ispor.org/docs/default-source/cti-meeting-21305-documents/a9048821-885f-4555-a75b-7bf3be5989e4.pdf)
56. [Lonze (2021)](https://pubmed.ncbi.nlm.nih.gov/33180664/)
57. [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)
58. [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)
59. [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)
60. [Maldonado et al. (2021)](https://www.lidsen.com/journals/transplantation/transplantation-05-02-143)
61. [Maldonado et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.14946)
62. [Mamode et al. (2022)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2022.10511/full)
63. [Mancebo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40209457/)
64. [Milhès et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755536/)
65. [National Institute of Diabetes and Digestive and Kidney Diseases](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what-is-kidney-failure)
66. [National Institute of Diabetes and Digestive and Kidney Diseases (2016)](https://www.niddk.nih.gov/health-information/kidney-disease/heart-disease)
67. [National Institute of Diabetes and Digestive and Kidney Diseases (2018)](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis)
68. [National Institute of Diabetes and Digestive and Kidney Diseases (2021)](https://www.niddk.nih.gov/health-information/kidney-disease/mineral-bone-disorder)
69. [NCPE (2024)](https://www.ncpe.ie/wp-content/uploads/2024/11/Imlifidase-Technical-Summary-23041.pdf)
70. [NICE TA809 committee discussion (2022)](https://www.nice.org.uk/guidance/TA809/chapter/3-committee-discussion)
71. [NICE TA809 information about imlifidase (2022)](https://www.nice.org.uk/guidance/ta809/chapter/2-Information-about-imlifidase)
72. [Osmani et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1111/trf.18447)
73. [Phelan and Turner (2025)](https://edren.org/ren/handbook/transplant-handbook/immunosuppression-protocol/imlifidase-enabled-transplantation/)
74. [Reuter et al. (2026a)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1846251/full)
75. [Reuter et al. (2026b)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1868642/full)
76. [Schinstock et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40373881/)
77. [Scottish Medicines Consortium (2022)](https://scottishmedicines.org.uk/medicines-advice/imlifidase-idefirix-full-smc2445/)
78. [SERB Pharmaceuticals (2026)](https://serb.com/news/serb-pharmaceuticals-completes-acquisition-of-european-and-mena-rights-to-idefirix-imlifidase-from-hansa-biopharma/)
79. [Swissmedic Idefirix risk management plan summary](https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/rmp/imlifidase_idefirix-rmp-summary.pdf.download.pdf/imlifidase_Idefirix_RMP-Summary.pdf)
80. [Therapeutic Goods Administration Idefirix product information (2024)](https://www.tga.gov.au/sites/default/files/2024-05/auspar-idefirix-240509-pi.pdf)
81. [Transplantation Society of Australia and New Zealand (2026)](https://tsanz.com.au/storage/Guidelines/TSANZ_Guidelines-for-Imlifidase-Supported-Kidney-Transplantation-in-Australia_final-2.pdf)
82. [Vo et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23511212/)
83. [Welsh Kidney Network (2026)](https://jcc.nhs.wales/clinical-policies/welsh-kidney-network/imlifidase-desensitisation-treatment-option-for-adults-who-are-awaiting-a-kidney-transplant-from-a-deceased-donor-policy-position-statement-pps256-january-2026/)
84. [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

## Related pages
- [Imlifidase: Kidney transplantation in highly sensitized patients](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Terms and abbreviations](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/terms-and-abbreviations.md)
- [Imlifidase: Kidney transplantation in highly sensitized patients](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/executive-summary) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/executive-summary.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Product information and disease description](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/product-information-and-disease-description.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Clinical evidence](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/clinical-evidence.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Economic information and modeling report](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/economics) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/economics.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: prevalence by geography](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/prevalence) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/prevalence.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/cost-effectiveness-analyses.md)
